Search research articles
Contact Us
Filters
Showing results (391-400 of 509) with videos related to
Page
of 51
Sort By:
Bulletin Du Cancer
|
March 26, 2023
Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer
Philipp Harter, Gerhard Bogner, Luis Chiva, et al.
JCO Oncology Practice
|
November 24, 2025
Predictors of Successful Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery in Management of Ovarian Cancer
Claudia Marchetti, Gwenael Ferron, Olivier Colomban, et al.
Cancers
|
July 14, 2023
Sorafenib in Molecularly Selected Cancer Patients: Final Analysis of the MOST-Plus Sorafenib Cohort
Olivier Trédan, Maud Toulmonde, Christophe Le Tourneau, et al.
Genome Medicine
|
December 19, 2024
Patterns of genomic instability in > 2000 patients with ovarian cancer across six clinical trials evaluating olaparib
Alan Barnicle, Isabelle Ray-Coquard, Etienne Rouleau, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 18, 2024
Homologous recombination deficiency in ovarian cancer: Global expert consensus on testing and a comparison of companion diagnostics
Stanislas Quesada, Frédérique Penault-Llorca, Xavier Matias-Guiu, et al.
International Journal of Cancer
|
August 6, 2019
Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer
Isabelle Ray-Coquard, David Cibula, Mansoor R Mirza, et al.
Journal of Personalized Medicine
|
October 27, 2022
Alterations in Homologous Recombination-Related Genes and Distinct Platinum Response in Metastatic Triple-Negative Breast Cancers: A Subgroup Analysis of the ProfiLER-01 Trial
Elise Bonnet, Véronique Haddad, Stanislas Quesada, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 1, 2017
Location of Mutation in <i>BRCA2</i> Gene and Survival in Patients with Ovarian Cancer
S Intidhar Labidi-Galy, Timothée Olivier, Manuel Rodrigues, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 28, 2023
PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial
Liselore Loverix, Ignace Vergote, Pieter Busschaert, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 12, 2024
Clinical evaluation of a low-coverage whole-genome test for detecting homologous recombination deficiency in ovarian cancer
Romain Boidot, Michael G B Blum, Marie-Pierre Wissler, et al.
Page
of 51
Search research articles
Search
Showing results (391-400 of 509) with videos related to
Sort By:
Page
of 51
Bulletin Du Cancer
|
March 26, 2023
Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer
Philipp Harter, Gerhard Bogner, Luis Chiva, et al.
JCO Oncology Practice
|
November 24, 2025
Predictors of Successful Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery in Management of Ovarian Cancer
Claudia Marchetti, Gwenael Ferron, Olivier Colomban, et al.
Cancers
|
July 14, 2023
Sorafenib in Molecularly Selected Cancer Patients: Final Analysis of the MOST-Plus Sorafenib Cohort
Olivier Trédan, Maud Toulmonde, Christophe Le Tourneau, et al.
Genome Medicine
|
December 19, 2024
Patterns of genomic instability in > 2000 patients with ovarian cancer across six clinical trials evaluating olaparib
Alan Barnicle, Isabelle Ray-Coquard, Etienne Rouleau, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 18, 2024
Homologous recombination deficiency in ovarian cancer: Global expert consensus on testing and a comparison of companion diagnostics
Stanislas Quesada, Frédérique Penault-Llorca, Xavier Matias-Guiu, et al.
International Journal of Cancer
|
August 6, 2019
Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer
Isabelle Ray-Coquard, David Cibula, Mansoor R Mirza, et al.
Journal of Personalized Medicine
|
October 27, 2022
Alterations in Homologous Recombination-Related Genes and Distinct Platinum Response in Metastatic Triple-Negative Breast Cancers: A Subgroup Analysis of the ProfiLER-01 Trial
Elise Bonnet, Véronique Haddad, Stanislas Quesada, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 1, 2017
Location of Mutation in <i>BRCA2</i> Gene and Survival in Patients with Ovarian Cancer
S Intidhar Labidi-Galy, Timothée Olivier, Manuel Rodrigues, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 28, 2023
PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial
Liselore Loverix, Ignace Vergote, Pieter Busschaert, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 12, 2024
Clinical evaluation of a low-coverage whole-genome test for detecting homologous recombination deficiency in ovarian cancer
Romain Boidot, Michael G B Blum, Marie-Pierre Wissler, et al.
Page
of 51